Table 1

Details of bacterial intracellular infections (salmonella and listeria)

Patient age/sex	Organism*	Site of infection	Pre/post 01 January 2006	Anti-TNF drug on entry into study	Anti-TNF drug at infection	Anti-TNF therapy within past 90 days
60/M	Listeria	Meningitis	Pre	Etanercept	Etanercept	Etanercept
60/M	Listeria	Meningitis	Post	Etanercept	Off drug	Off drug
47/M	Listeria	Meningitis	Pre	Infliximab	Infliximab	Infliximab
60/M	Listeria	Septicaemia	Pre	Infliximab	Infliximab	Infliximab
70/F	Listeria	Septicaemia	Post	Infliximab	Infliximab	Infliximab
57/F	Listeria monocytogenes	Septicaemia	Post	Adalimumab	Infliximab	Infliximab
59/M	Listeria monocytogenes	Septicaemia	Post	Adalimumab	Adalimumab	Adalimumab
60/F	Listeria monocytogenes	Septic arthritis	Pre	Adalimumab	Adalimumab	Adalimumab
67/M	Listeria monocytogenes	Septic arthritis	Pre	Etanercept	Etanercept	Etanercept
49/F	Salmonella	Gastrointestinal	Post	Etanercept	Off drug	Etanercept
54/F	Salmonella	Gastrointestinal	Pre	Etanercept	Off drug	Etanercept
76/M	Salmonella	Salmonellosis	Pre	Etanercept	Off drug	Off drug
57/F	Salmonella	Septic arthritis	Pre	Infliximab	Infliximab	Infliximab
70/F	Salmonella	Gastrointestinal	Post	Infliximab	Infliximab	Infliximab
57/F	Salmonella enteritidis	Septicaemia	Pre	Adalimumab	Adalimumab	Adalimumab